Riesgo de acidosis láctica fatal y no fatal con el uso de metformina para la diabetes mellitus tipo 2
Characteristics of included studies Outcomes
C-reactive proteitn, complement factor C3
Notes Allocation concealment
D
Study
Cavallo-Perin 1989
Methods
TRIAL DESIGN: Double-blind crossover randomised controlled trial DURATION: 6 months
Participants
COUNTRY: Italy SETTING: outpatient Treatment N: 10 Control N: 10 AGE: 51+/-2.1 SEX: 60% men INCLUSION: Type 2 DM EXCLUSIONS: liver or kidney disease, heart failure, other drugs, or chronic infection
Interventions
TREATMENT: Metformin 850 mg BID CONTROL: phenformin 50 mg BID (not analysed)
Outcomes
Weight, glucose, HbA1, and blood lactate levels at different times of day.
Notes Allocation concealment
A
Study
Cefalu 2002
Methods
TRIAL DESIGN: Open-label randomised controlled trial DURATION: 4.5 months
Participants
COUNTRY: United States SETTING: outpatient Treatment N: 91 Control N: 91 Age: 35-70 Sex: not stated Inclusion: type 2 DM Exclusion: not stated
Interventions
TREATMENT: metformin 850 mg TID with and without glipizide CONTROL: glipizide 20 mg/day
Outcomes
Glycemic control, body weight, abdominal fat distribution, PAI-1 levels
Notes Allocation concealment
D
Study
Chakrabarti 1965
Methods
TRIAL DESIGN: Single-blind crossover comparative trial; not randomised DURATION: 2 months placebo, 4 months treatment
Participants
COUNTRY: United Kingdom SETTING: outpatient Treatment N: 27 Control N: 27 AGE: 56.3 SEX: 95% men INCLUSION: Type 2 DM with coronary artey disease, claudication EXCLUSIONS: none listed Página 34
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.